Spruce Historical Income Statement

SPRB Stock  USD 0.55  0.02  3.77%   
Historical analysis of Spruce Biosciences income statement accounts such as Total Revenue of 10.6 M, Other Operating Expenses of 37.4 M, Research Development of 29 M or Total Operating Expenses of 37.4 M can show how well Spruce Biosciences performed in making a profits. Evaluating Spruce Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Spruce Biosciences's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Spruce Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Spruce Biosciences is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.

About Spruce Income Statement Analysis

Spruce Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Spruce Biosciences shareholders. The income statement also shows Spruce investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Spruce Biosciences Income Statement Chart

At present, Spruce Biosciences' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 4.3 M, whereas Depreciation And Amortization is forecasted to decline to about 66.5 K.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Spruce Biosciences. It is also known as Spruce Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.
Most accounts from Spruce Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Spruce Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.At present, Spruce Biosciences' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 4.3 M, whereas Depreciation And Amortization is forecasted to decline to about 66.5 K.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation68K74K78K49.3K
Total Operating Expenses42.1M47.3M62.1M37.4M

Spruce Biosciences income statement Correlations

0.780.67-0.68-0.68-0.690.63-0.690.670.78-0.690.06-0.69-0.480.02-0.020.740.190.03
0.780.98-0.97-0.96-0.960.97-0.960.981.0-0.960.61-0.96-0.44-0.570.560.970.73-0.47
0.670.98-0.97-0.96-0.961.0-0.961.00.98-0.960.69-0.96-0.4-0.670.650.950.82-0.53
-0.68-0.97-0.971.01.0-0.961.0-0.97-0.971.0-0.731.00.420.7-0.69-0.92-0.770.64
-0.68-0.96-0.961.01.0-0.951.0-0.96-0.961.0-0.731.00.40.7-0.7-0.9-0.750.66
-0.69-0.96-0.961.01.0-0.951.0-0.96-0.971.0-0.721.00.40.68-0.68-0.9-0.740.65
0.630.971.0-0.96-0.95-0.95-0.951.00.97-0.950.71-0.95-0.39-0.70.680.930.84-0.54
-0.69-0.96-0.961.01.01.0-0.95-0.96-0.971.0-0.721.00.40.69-0.69-0.9-0.740.65
0.670.981.0-0.97-0.96-0.961.0-0.960.98-0.960.69-0.96-0.4-0.670.650.950.82-0.53
0.781.00.98-0.97-0.96-0.970.97-0.970.98-0.970.6-0.97-0.42-0.570.560.950.72-0.47
-0.69-0.96-0.961.01.01.0-0.951.0-0.96-0.97-0.721.00.40.68-0.68-0.9-0.740.65
0.060.610.69-0.73-0.73-0.720.71-0.720.690.6-0.72-0.72-0.36-0.980.980.610.92-0.93
-0.69-0.96-0.961.01.01.0-0.951.0-0.96-0.971.0-0.720.390.69-0.69-0.9-0.740.65
-0.48-0.44-0.40.420.40.4-0.390.4-0.4-0.420.4-0.360.390.17-0.17-0.49-0.430.16
0.02-0.57-0.670.70.70.68-0.70.69-0.67-0.570.68-0.980.690.17-1.0-0.58-0.90.93
-0.020.560.65-0.69-0.7-0.680.68-0.690.650.56-0.680.98-0.69-0.17-1.00.570.88-0.95
0.740.970.95-0.92-0.9-0.90.93-0.90.950.95-0.90.61-0.9-0.49-0.580.570.75-0.45
0.190.730.82-0.77-0.75-0.740.84-0.740.820.72-0.740.92-0.74-0.43-0.90.880.75-0.73
0.03-0.47-0.530.640.660.65-0.540.65-0.53-0.470.65-0.930.650.160.93-0.95-0.45-0.73
Click cells to compare fundamentals

Spruce Biosciences Account Relationship Matchups

Spruce Biosciences income statement Accounts

201920202021202220232024 (projected)
Net Interest Income(65K)(323K)(345K)1.1M3.8M4.0M
Depreciation And Amortization96K102K381K429K70K66.5K
Interest Expense65K323K345K420K483K299.9K
Selling General Administrative2.3M5.6M11.4M12.1M12.7M8.3M
Other Operating Expenses13.1M29.4M42.1M47.3M62.1M37.4M
Operating Income(13.1M)(29.4M)(42.1M)(47.3M)(52.0M)(49.4M)
Net Income From Continuing Ops(13.1M)(29.5M)(42.3M)(46.2M)(49.1M)(51.6M)
Ebit(13.1M)(29.2M)(41.9M)(45.8M)(47.4M)(49.8M)
Research Development10.8M23.9M30.7M35.2M49.4M29.0M
Ebitda(13.0M)(29.1M)(41.6M)(45.3M)(47.4M)(49.7M)
Total Operating Expenses13.1M29.4M42.1M47.3M62.1M37.4M
Reconciled Depreciation12K36K68K74K78K49.3K
Income Before Tax(13.1M)(29.5M)(42.3M)(46.2M)(47.9M)(50.3M)
Total Other Income Expense Net19K(123K)(226K)1.1M4.1M4.3M
Net Income Applicable To Common Shares(13.1M)(29.5M)(42.3M)(46.2M)(41.6M)(43.6M)
Net Income(13.2M)(30.0M)(42.7M)(45.1M)(47.9M)(50.3M)
Income Tax Expense149K487K396K(1.1M)(97.9K)(93.0K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.95)
Revenue Per Share
0.173
Quarterly Revenue Growth
(0.80)
Return On Assets
(0.30)
Return On Equity
(0.58)
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.